Single-center prospective observational study to evaluate the relationship between the anti-heart failure effects of Sacubitril/Valsartan and genetic polymorphisms.

Single-center prospective observational study to evaluate the relationship between the anti-heart failure effects of Sacubitril/Valsartan and genetic polymorphisms. - Genomic pharmacology research on ARNI.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056429

Enrollment

100

Registered

2024-12-11

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure Acute heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are 20 years of age or older at the time of consent. Patients with heart failure symptoms of NYHA classification II or higher. Patients newly introduced to Sacubitril/Valsartan as treatment for heart failure. Patients who have been fully informed of the study and who have given written consent of their own free will.

Exclusion criteria

Exclusion criteria: Patients with significantly poor medication adherence Patients with advanced cancer Patients with a history of autoimmune disease. Patients with severe hepatic dysfunction. (Total bilirubin 2 mg/dl or more) Patients with severe renal dysfunction. (Creatine 2 mg/dl or more) Patients deemed inappropriate by the attending physician, etc.

Design outcomes

Primary

Measure	Time frame
Hospitalization due to exacerbation of heart failure Cardiovascular events heart disease-related death	—

Secondary

Measure	Time frame
NT-proBNP BNP sST2 All-cause death	—

Countries

Japan

Contacts

Public ContactKoji Suzuki

Hamamatsu University School of Medicine Hospital Pharmacy

kojisuzu@hama-med.ac.jp053-435-2767

Outcome results